Background Dopaminergic neuronal loss in Parkinson's disease leads to changes in the
circuitry of the basal ganglia, such as decreased inhibitory GABAergic input to the subthalamic …

Background Gene transfer of glutamic acid decarboxylase (GAD) and other methods that
modulate production of GABA in the subthalamic nucleus improve basal ganglia function in …

The differential diagnosis of parkinsonian disorders can be challenging, especially early in
the disease course. PET imaging with [ 18 F]-fluorodeoxyglucose (FDG) has been used to …

Parkinson's disease (PD) is associated with abnormal activity in spatially distributed neural
systems mediating the motor and cognitive manifestations of this disorder. Metabolic PET …

It has been proposed that deep brain stimulation (DBS) of the subthalamic nucleus (STN
DBS) and dopaminergic therapy ameliorate the symptoms of Parkinson’s disease through …

Background Idiopathic Parkinson's disease can present with symptoms similar to those of
multiple system atrophy or progressive supranuclear palsy. We aimed to assess whether …

Importance Coenzyme Q10 (CoQ10), an antioxidant that supports mitochondrial function, has
been shown in preclinical Parkinson disease (PD) models to reduce the loss of dopamine …

Persistent dyskinesias in the absence of or with only minimal amounts of dopaminergic
medication have been reported after dopamine cell implantation for Parkinson's disease. In this …

Objective: To determine whether providing remote neurologic care into the homes of people
with Parkinson disease (PD) is feasible, beneficial, and valuable. Methods: In a 1-year …

Parkinson's disease (PD) is a neurodegenerative movement disorder presenting with subcortical
pathology and characterized by motor deficits. However, as is frequently reported in the …